Abstract
Interest continues to grow rapidly in clinical gene therapy. Although many protocols approved by the US NIH Recombinant Advisory Committee involve the genetic marking of cells to determine, for example, the source of relapse after autologous bone marrow transplantation for certain malignancies (1), increasing numbers are concerned with the correction of inherited single-gene disorders.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
